HeartBeam (NASDAQ: BEAT), a medical technology company focused on cardiac care innovation, has announced the commencement of an underwritten public offering of shares of its common stock or common stock equivalents. The offering is subject to market conditions, with all securities to be offered by the company. The final size and terms of the offering will depend on market conditions. HeartBeam intends to use the net proceeds to advance the commercialization of its FDA-cleared 12-lead synthesized ECG system, further develop its extended-wear patch and heart attack detection initiatives, enhance its artificial intelligence capabilities, and support working capital and general corporate purposes. Titan Partners, a division of American Capital Partners, is acting as the sole bookrunner for the offering.
The company's technology represents a significant advancement in cardiac care. HeartBeam is creating the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing those signals into a 12-lead ECG. This platform is designed for portable devices that can be used wherever the patient is, enabling physicians to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of a medical facility. The company's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and its 12-lead ECG synthesis software received clearance in December 2025. HeartBeam holds over 20 issued patents related to its technology.
The offering comes at a critical time as HeartBeam seeks to scale its commercial operations and invest in AI-driven analytics. The company's focus on heart attack detection is particularly important, given that heart disease remains a leading cause of death globally. By enhancing its AI capabilities, HeartBeam aims to improve the accuracy and speed of cardiac event detection, potentially saving lives through earlier intervention. The extended-wear patch development also addresses a key market need for continuous monitoring solutions that can detect arrhythmias and other conditions over longer periods.
While the offering provides a pathway to fund these initiatives, investors should consider the forward-looking statements and associated risks. As noted in the company's filings with the SEC, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, there are risks and uncertainties that could cause actual results to differ materially from expectations. These include market conditions, regulatory challenges, and competition in the medical technology space.
For more details on the offering and HeartBeam's technology, visit the full press release at https://ibn.fm/pxFOz. The latest news and updates relating to BEAT are available in the company's newsroom at https://ibn.fm/BEAT.
